OBJECTIVES: Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma generally associated with poor prognosis. To advance our understanding of MCL treatments on patients’ quality of life (QoL), a systematic literature review was performed to identify commonly utilized patient-reported outcomes (PROs) in MCL.

METHODS: A systematic literature search in Medline, Embase, and Google/Google Scholar between 01/01/1999 and 07/31/2019 was conducted per PRISMA guidelines. Inclusion criteria included all MCL publications that evaluated PROs in patients of all ages and lines of therapy in clinical trials or real-world studies. Results were summarized descriptively by a) type of PRO instrument; and b) treatments for MCL.

RESULTS: Nineteen studies met inclusion criteria. EQ-5D was the most common ­QoL instrument identified (6/19, 31.6%), followed by FACT-Lymphoma (Lym) and EORTC QLQ-C30 (5/19, 26.3% each). Of the 16 studies reporting PRO, chemo(immuno)therapy and targeted therapies were the most studied regimens (n=7 each). Among chemo(immuno)therapy regimens, 85.7% (6/7) showed worsening or no improvement in QoL (BR; R-CHOP; radioimmunotherapy with 90Y-ibritumomab tiuxetan; modified R-CHOP; R-CyBor-D; surgery+chemotherapy) versus baseline or comparators. One study (RT-PEP(C3)) reported maintained or improved QoL from baseline. Among targeted regimens (n=7), all studies of single-agent ibrutinib (3/3) showed improvement in QoL versus baseline (n=2) or comparator (n=1; temsirolimus), while the majority of remaining regimens (75%; 3/4) showed worsening or no improvement in QoL (rituximab maintenance; lenalidomide; enzastaurin) compared to baseline or observation. One study (lenalidomide+rituximab) reported maintained or improved QoL compared to baseline.

CONCLUSIONS: EQ-5D was the most commonly utilized tool for evaluating PROs in patients with MCL. Most chemo(immuno)therapy regimens reported worsening or no improvement in QoL. Single-agent ibrutinib demonstrated QoL improvement versus baseline or comparator in all 3 studies. Given the changing treatment landscape, future studies should continue evaluating PROs to improve the quality of care delivered to patients with MCL.